Search > Chronic Lymphocytic Leukemia
My employer runs this trial

Epcoritamab for CLL

CF
Uo
Overseen ByUniversity of California Irvine Medical
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of California, Irvine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).

Who Is on the Research Team?

CC

Catherine C Coombs, MD

Principal Investigator

Chao Family Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for people with chronic lymphocytic leukemia (CLL) who are already being treated with a BTK inhibitor but still have high-risk disease. Participants should be adults and meet certain health requirements set by the study.

Inclusion Criteria

ALC ≤10 K/mcL
I have CLL and at least one high-risk factor like prior therapy, 17p deletion, or TP53 mutation.
I am currently taking or can get a BTK inhibitor medication.
See 5 more

Exclusion Criteria

Pregnant or breastfeeding
I do not have another active cancer needing treatment, except certain skin or hormone-related cancers.
I currently have an immune-related blood cell disorder.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Epcoritamab

Trial Overview

The study is testing Epcoritamab, given as an additional treatment to see if it helps control CLL better in patients already on BTK inhibitors. All participants receive Epcoritamab; there is no comparison group.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: EpcoritamabExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Irvine

Lead Sponsor

Trials
580
Recruited
4,943,000+

Genmab

Industry Sponsor

Trials
76
Recruited
15,300+

Dr. Jan van de Winkel

Genmab

Chief Executive Officer since 2010

PhD in Immunology, University of Utrecht

Dr. Judith Klimovsky

Genmab

Chief Medical Officer since 2019

MD, University of Copenhagen

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.